Program Announcement for the Defense Health Agency

Bone Marrow Failure Research Program

Idea Development Award

Funding Opportunity Number: HT942526BMFRPIDA

Pre-Application Due: August 5, 2026

Application Due: November 4, 2026

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click ⓘ to be taken to additional guidance and instructions within the General Application Instructions (GAI).

1. Basic Information About the Funding Opportunity

Summary: The BMFRP Idea Development Award (IDA) is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP's vision of understanding and curing BMF diseases.

Distinctive Features:

- This funding opportunity is open to Established Investigators (EIs) and Early-Career Investigators (ECIs). Reviewers will assess Principal Investigators (PIs) using distinct review criteria based on their eligibility as an EI or ECI.
- Preliminary data is not required. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $4.0M to fund approximately five Idea Development Award applications with total cost caps of $0.8M per award. The maximum period of performance is 3 years. It is anticipated that awards made from this fiscal year 2026 (FY26) funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Preproposal) Submission Deadline:** 5:00 p.m. Eastern Time (ET), August 5, 2026
- **Invitation to Submit an Application:** September 16, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, November 4, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, November 12, 2026
- **Peer Review:** January 2027
- **Programmatic Review:** March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526BMFRPIDA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

2.1.2. Principal Investigator

Independent investigators affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citizenship status.

An investigator may be named as a PI on a maximum of two applications to this program announcement. If an investigator is named as a PI on more than two BMFRP IDA applications, only the first two applications received will be accepted; additional applications will be administratively withdrawn.

Established Investigators: Investigators who are 10 or more years from obtaining their first appointment as an independent investigator at the time of the application submission deadline are eligible to be named as the EI on the application. The EI should demonstrate BMF disease-related expertise and background through their funding and publication record. The EI should plan research collaborations and dedicate a level of effort that is appropriate for the successful conduct of the proposed work.

Early-Career Investigators: Investigators who are less than 10 years from obtaining their first appointment as an independent investigator at the time of the application submission deadline are eligible to be named as the ECI on the application. Time spent on extended family medical leave will not count against the 10-year eligibility restriction, and associated lapses in research time and appointments should be articulated in the application. The biographical sketch should clearly articulate the PI's current appointment status and aggregate time from first appointment as an independent investigator. ***Postdoctoral or clinical fellows are not eligible for ECI designation***. The ECI's training should demonstrate the ability to accomplish the proposed work. The PI should demonstrate institutional commitment beyond financial backing such as, but not limited to, independent laboratory space, dedicated research time and potential collaborations. The ECI should propose to dedicate a level of effort for the proposed work that is appropriate to successfully conduct the research project.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional recipient qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Bone Marrow Failure Research Program (BMFRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the BMFRP in 2008 to provide support for research that has high potential impact and exceptional scientific merit in bone marrow failure. Appropriations for the BMFRP from FY08 through FY24 totaled $71.55 million (M). FY26 appropriation is $7.50M.

The vision of the BMFRP is to understand and cure BMF diseases. The program challenges the scientific community to design innovative research of inherited and acquired BMF diseases to improve understanding of the pathobiology and advance prevention and treatment. Through these efforts, the BMFRP seeks to improve the health of affected Service Members, Veterans and the general public, with the ultimate goal of cure.

BMFRP Objective

The BMFRP objective is to fund research in the areas of inherited or acquired BMF. Studies focused on BMF syndromes and their progression to other malignancies, such as leukemia, are acceptable. ***However, the BMFRP will not consider research with a primary focus on myeloproliferative neoplasms, leukemia or other malignancies.*** *Applications proposing* stem cell biology studies and translational projects, including bone marrow transplantation studies and cellular therapies, should be clearly related to BMF diseases.

*Projects related to **Graft Versus Host Disease** (GVHD) must explain how the issues the proposed research is investigating are **specifically relevant to BMF**, but not other stem cell transplant patients. Applications should describe the experimental design **for using BMF models** to directly test the proposed hypotheses. The BMFRP will not consider GVHD studies in other hematological disorders.*

The BMFRP encourages research that improves the understanding and treatment of BMF diseases and conditions. To assist the application review process, applicants **must** specify the type(s) of disease or condition that will be the primary focus of the investigation. The following is a non-exhaustive list of diseases and conditions that are relevant to the objective of the BMFRP:

- Aplastic Anemia
- Diamond-Blackfan Anemia
- Dyskeratosis Congenita/Telomere Biology Disorders
- Fanconi Anemia
- GATA2 Deficiency
- Induced BMF: Radiation/Chemical
- Myelodysplastic Syndromes
- Paroxysmal Nocturnal Hemoglobinuria
- Pearson Syndrome
- SAMD9/SAMD9L Germline Mutations
- Severe Congenital Neutropenia
- Shwachman-Diamond Syndrome
- VEXAS Syndrome
- Adenosine Deaminase 2 Deficiency

If the proposed research project focuses on a disease that is not listed, the application should clearly identify the disease or condition that is central to the study and provide justification that

the proposed research project meets the objective of the BMFRP. If the proposed research project is not specific for one disease or condition and will address multiple diseases or conditions, the application should clearly articulate the BMF communities that will benefit from the study.

3.1. Award History

The BMFRP Award mechanism was first offered in FY13. Since then, 367 Idea Development Award applications were received, and 72 were recommended for funding.

3.2. Intent of the Idea Development Award

The BMFRP Idea Development Award (IDA) is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP's vision of understanding and curing BMF diseases. The proposed research should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. This award mechanism supports new ideas that are expected to generate data for future avenues of scientific investigation. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data. ***This mechanism encourages hypothesis-driven correlative studies associated with clinical trials and/or clinical samples.*** Applications proposing correlative studies must have demonstrated access to samples and/or patient populations and the proposed study should represent new avenues of research that will advance the understanding of disease biology, treatment mechanisms or other innovative and impactful outcomes in BMF. **Funding to conduct the clinical trial itself is outside the scope of this award mechanism.**

3.2.1. Focus Areas for the IDA

To meet the intent of the funding opportunity, applications **must** address at least one of the FY26 BMFRP focus areas listed below.

- Find effective BMF treatments and cures
- Understand the causes and progression of BMF diseases

3.2.2. Key Elements for the IDA

The following are significant features of this award mechanism:

- **Innovation:** Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, reveal new avenues of investigation or exhibit other creative qualities. This may include high-risk, potentially high-gain, approaches to BMF disease research. Research that is only an incremental advance is *not* considered innovative.
- **Impact:** Proposed research projects should address a central critical issue or question in BMF disease research and/or patient care. High-impact research, if successful, will significantly advance current methods and concepts for the prevention, detection, diagnosis and/or treatment of BMF diseases.
- **Scientific Rationale and Feasibility:** Projects must include a well-formulated, testable hypothesis based on strong scientific rationale and evidence that the applicant can complete the proposed work. Preliminary data is not required. While the inclusion of preliminary data

is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach.

- **Translational Potential:** The application should consider the potential for translation of the project, even if the translational potential is long-term and anticipated to occur well beyond the end of the proposed project. Applications should describe how the research will translate findings into an understanding of causes or progression of BMF diseases, or strategies for prevention or a cure.
- **Personnel:** The application should demonstrate expertise in BMF diseases through the Principal Investigator's (PI's) background or that of the research team or through collaboration. The application should document all collaborations. ECIs must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of BMF research; however, the PI is not required to have previous BMF research experience.

3.2.3. Other Important Considerations for the IDA

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Clinical trials are not allowed within this funding opportunity.

***For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research*, which is allowed.**

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE, CONSORT, SPIRIT and ARRIVE 2.0 guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

Period of Performance: The maximum period of performance is **3** years.

Cost Cap: The application's total costs budgeted for the entire period of performance should not exceed **$800,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for two investigators to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the BMFRP IDA.
- Costs for correlative studies associated with a clinical trial(s), if applicable.

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Clinical trial costs.

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a ***pre-application*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

Pre-application submissions must include the following components.

Upload documents as individual PDF files unless otherwise noted. Files must comply with the formatting guidelines listed in the GAI.

- **Preproposal Narrative (two-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

  The Preproposal Narrative should include the following:

  - **Objective:** State the objective of the proposed study. Identify the FY26 BMFRP Focus Area(s) the proposed research will address and describe how the study meets the intent of the award mechanism.
  - **Research Idea:** Briefly state the rationale, hypothesis/objective and specific aims of the proposed research. Present the ideas and reasoning behind the proposed study, while considering data/evidence to support its feasibility. Explain how the project addresses a critical problem in BMF research. For correlative studies linked to a clinical trial(s) and/or clinical samples, describe how the study generates new hypotheses or advances understanding of disease biology, treatment mechanisms or other impactful outcomes to enhance the trial's impact.
  - **Innovation:** Explain how the research introduces new paradigms, challenges existing ones, offers fresh perspectives on existing problems or demonstrates other creative qualities.
  - **Impact:** Describe the potential impact of the research and how it advances the BMFRP's vision to understand and cure BMF diseases.
  - **Personnel:** Describe the BMF expertise of the PI and research team and its relevance to successfully completing the proposed research. Specify the PI's eligibility as an EI or ECI.
- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application ***must be uploaded as individual files*** and are limited to the following:

- **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title and reference source, including volume, chapter, page numbers and publisher, as appropriate).
- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols used in the Preproposal Narrative.
- **Key Personnel Biographical Sketches:** ***All biographical sketches should be uploaded as a single combined file.*** Biographical sketches should be used to demonstrate background and expertise through education, positions, publications and previous work accomplished.

4.3. Full Application Components

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected.

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*:

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during pre-application submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

- **Attachment 1: Project Narrative (10-page limit): Upload as "ProjectNarrative.pdf".**

  Describe the proposed project in detail using the outline below.

  - **Background:** Present the rationale behind the proposed study and explain how this research demonstrates a critical understanding and in-depth analysis of BMF diseases. Highlight relevant prior experience. Include a well-formulated testable hypothesis based on strong scientific rationale and evidence that the proposed work can be completed. Preliminary data is not required. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach.
  - **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached. Identify the FY26 BMFRP Focus Area(s) the work seeks to address.
  - **Specific Aims:** Concisely explain the project's specific aims. If this research project is part of a larger study, present only the tasks that this award would fund.
  - **Research Strategy:**
    - Provide a detailed description of the experimental design, methods, analyses and appropriate controls to enable evaluation of their feasibility and appropriateness.
    - If applicable, describe the prospective sample collection or ongoing clinical trial(s) the proposed study will correlate to and provide the clinicaltrials.gov ID number(s), if available.

- Address potential problem areas and pitfalls, and present alternate methods and approaches.
- Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.
- Describe the outcome measures to be captured and plans for data analysis.
- Describe the data reporting process and how documentation will support potential regulatory filings with the U.S. Food and Drug Administration (FDA) or international regulatory agencies, if applicable.
- Research projects may involve preclinical studies in animal models, human subjects or human anatomical substances. If using human data sets, specimens (e.g., blood, tumor tissue) or participants, provide evidence of availability and access to the required specimens or populations. Include a detailed plan for sample acquisition, participant recruitment and securing additional research resources. For projects utilizing data sets or specimens from biobanks, repositories or clinical trials, applicants must ***provide letter(s) of collaboration (see Attachment 2) from the manager or lead investigator confirming access and commitment to providing the data sets or specimens, if they are not named as the PI or key personnel on the application.***
- For all applications proposing clinical research describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial and ethnic group, and an accompanying rationale for the selection of subjects. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity should be provided as part of the application's Supporting Documentation (Attachment 2).

– **Statistical Plan:** Clearly describe the statistical plan and rationale for the statistical methodology and explain how it is appropriate for the proposed study. Provide a sample size estimate and the method by which it was derived, including power analysis calculation, as applicable. Include any plans for blinding and randomization.

○ **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".**

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

References Cited: List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols.

Facilities, Existing Equipment and Other Resources: Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so,

reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Organizational Support: Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should also confirm that the PI(s) meets the eligibility criteria. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

Letters of Access *(if applicable)*: If access to patients, patient samples, patient datasets or other resources is necessary to conduct the study, and the PI or key personnel on this application does not own the resource, provide a letter of collaboration signed by the appropriate authorizing individual confirming access to the resource.

Intellectual Property: Information can be found in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.315), "Intangible Property."

- **Intellectual and Material Property Plan *(if applicable)*:** Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Commercialization Strategy *(if applicable)*:** Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated and the potential commercial use for the technology being developed.

Inclusion Enrollment Report *(only required if clinical research is proposed)*: Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the "Public Health Service (PHS) Inclusion Enrollment Report", a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race and ethnicity. Studies utilizing biospecimens/datasets or resources that cannot be linked to a specific individual, sex, ethnicity, or race are exempt from this requirement. If an application is adding an aim to conduct biosample collection and biomarker analysis to an existing clinical trial that is supported by a different source of funding, use of the patients enrolled in that trial is expected and the study potentially may not include diverse populations. These applications are exempt from this requirement.

Sex as a Biological Variable Strategy (two-page limit is recommended): Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex

differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

Research Sharing Plan: Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".**

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

Background: Present the scientific rationale behind the proposed research project. If proposing a correlative study to an existing clinical trial(s), provide the clinicaltrials.gov ID number(s), if available.

Hypothesis/Objective(s): State the hypothesis to be tested and/or objective(s) to be reached. Identify the FY26 BMFRP focus area(s) the work seeks to address.

Specific Aims: State the specific aims of the study.

Study Design: Describe the study design, including appropriate controls.

Innovation: Briefly describe the novelty or paradigm shift proposed in the project and how it will yield critical discoveries, new avenues of investigation or major advancements to cure BMF diseases.

Military Relevance: Describe how the study is relevant to military health, if applicable.

- **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".**

  The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

  - State the FY26 BMFRP Focus Area(s) to be addressed by the proposed research.
  - Describe the objectives and rationale for the proposed research.
    - Describe the ultimate applicability of the research.
    - What bone marrow disease or condition is the study seeking to address and how will it help?
    - What are the potential clinical applications, benefits and risks?
  - Describe the innovative aspects of the proposed research project.
  - If the proposed research is too early for immediate clinical applicability, then describe the interim outcomes.
  - What are the likely contributions of the proposed research project to advancing the field of BMF research and/or patient care among those with BMF diseases/conditions?
    - What is the projected time it may take to achieve a person-related outcome?

- **Attachment 5: Statement of Work (four-page limit): Upload as "SOW.pdf".** Refer to eBRAP for the Suggested SOW Format.

  For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

- **Attachment 6: Innovation Statement (one-page limit): Upload as "Innovation.pdf".**
  - Summarize how the proposed work is innovative.
  - Describe how the proposed research project introduces a new paradigm or challenges existing paradigms in one or more of the following ways: concept or question, research methods or technologies, adaptations of existing methods or technologies, or looks at existing problems or issues from a new perspective.
  - Describe how the research represents more than an incremental advance on published data or current work in the applicant's laboratory.
  - Explain how the potential level of gain for the research and/or patient community justifies the risk of the proposed research project.
  - If a correlative study, explain how it will facilitate the generation of new hypotheses or advance the understanding of disease biology, treatment mechanisms or other innovative outcomes.

- **Attachment 7: Impact Statement (one-page limit): Upload as "Impact.pdf".** ***The impact statement should be written with a broad audience in mind, including readers without a background in science or medicine.***
  - Describe how the proposed research project addresses the FY26 BMFRP Focus Area(s) and is important to understanding the causes and progression of BMF diseases, realizing improvements in patient care and/or finding a cure.
  - Describe the short-term impact: Detail the anticipated outcome(s)/product(s) (intellectual and/or tangible) that will directly result from the proposed research and explain how the outcomes will drive the BMF field forward and support new avenues for research or clinical care.
  - Describe the long-term impact: Explain the potential long-term impact of this study on the field of BMF disease research and/or patient care.
  - If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Attachment 8: Translation Potential Statement (one-page limit): Upload as "Translation.pdf".** The potential for translation of the project should be considered even if translation is considered a long-term goal and anticipated to occur well beyond the end of the proposed project.
  - Include a description of the next steps in the translation of the results of this research after the end of the project.
  - Include a brief description of any collaborations with clinicians or physician-scientists for the proposed study. Describe how the research team will leverage these relationships to ensure potential translation of study finding in the future.
- **Attachment 9: Early-Career Investigator Eligibility Statement, required for the ECI Option (one-page limit): Upload as "ECIeligibility.pdf".** Provide a letter signed by the PI and the Department Chair, or equivalent official to verify that the eligibility requirements have been met. The letter should verify that the PI is an independent investigator who is less than 10 years from obtaining their first faculty appointment (or equivalent) at the time of the application submission deadline. Include the organizational commitment for independent laboratory space and protection of dedicated research time to conduct the proposed project. A suggested Early-Career Investigator Eligibility Statement template is available for download on the Full Announcement page in Grants.gov. For more eligibility details, refer to Section 3.2.2., Key Elements for the Idea Development Award, and Section 2.1.2., Principal Investigator.
- **Attachment 10: Representations** ***(Grants.gov submissions only)*****: Upload as "RequiredReps.pdf".** All extramural applicants must complete and submit the Required Representations document available on eBRAP.
- **Attachment 11: Suggested Intragovernmental/Intramural Budget Form** ***(if applicable)*****: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

Grants.gov	eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

  Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526BMFRPIDA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI through eBRAP.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The

eBRAP log number, application title and all information for the PI, Business Official(s), performing organization and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

When starting the pre-application, PIs should select a Mechanism Option appropriate to their pre-application:

Application Includes:	Select Mechanism Option:
Established Investigator	Idea Development Award - Established Investigator (IDA-EI)
Early-Career Investigator	Idea Development Award - Early Career Investigator (IDA-ECI)

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the application verification period ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.

Members of the FY26 BMFRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 BMFRP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

To determine the merits of the pre-application and the relevance to the mission of the BMFRP, pre-applications will be screened based on the following criteria:

- **Objective:** How well the proposed research adheres to the intent of the award mechanism. Whether the proposed research addresses at least one of the FY26 BMFRP Focus Areas.
- **Research Idea:**
    - Whether the scientific rationale supports the project objectives, specific aims and feasibility.
    - Whether the pre-application describes how the proposed experiments demonstrate the testability of the hypothesis.
- **Innovation:** How well the research proposes new paradigms, challenges existing paradigms, looks at existing problems from new perspectives or exhibits other creative qualities.
- **Impact:** To what degree the proposed research will make an important contribution that significantly advances current methods and concepts toward the BMFRP's vision of understanding and curing BMF diseases.

- **Personnel:**
  - Whether the PI meets the eligibility requirements as an EI or ECI.
  - To what degree the background of the PI and research team and their BMF disease-related expertise are suitable to successfully execute the proposed research.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance.

- **Research Strategy and Feasibility**
  - To what degree the scientific rationale supports the project and its feasibility, as demonstrated by a critical review and analysis of the literature, supporting proof-of-concept data, evidence that the proposed work can be completed, BMF disease-relevant preliminary data (if provided) and logical reasoning.
  - To what degree the proposed research demonstrates a critical understanding and in-depth knowledge of BMF diseases.
  - How well the hypotheses or objectives, specific aims, experimental design, methods and analyses are developed and integrated into the project.
  - To what degree the research design and methods can successfully achieve the goals of the proposed project.
  - How well studies are designed to achieve reproducible and rigorous results, including the choice of model and the endpoints/outcomes to be measured.
  - To what extent the application identifies potential problems and pitfalls and addresses alternative approaches.
  - Whether the application demonstrates the availability of resources such as tissue, data or human subjects, if applicable.
  - Whether the associated clinical trial(s) is described in sufficient detail to assess the relevance and appropriateness of the proposed correlative study, if proposed.
  - If applicable, whether there is sufficient evidence of collaboration with the lead investigator of the associated clinical trial(s), or that the PI or key investigator of this application is also the lead investigator of the associated clinical trial(s).
  - If applicable, whether a strategy for the inclusion of women and minorities appropriate to the objectives of the study was included and to what degree the rationale supports the composition of the proposed study population in terms of sex, racial and ethnic group.
  - Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single-sex study is sufficiently strong.
  - Whether the application sufficiently describes appropriate outcome measures and data analyses for the proposed study. If applicable, whether data will be appropriately reported and documented to support a regulatory filing with the FDA or an international regulatory agency.

- **Statistical Plan**
  - To what degree the statistical plan is appropriate for the proposed project, including any plans for blinding and randomization, as applicable.
  - How well the proposed sample size and the method by which it was derived, including power analysis calculation, are appropriate, as applicable.
- **Innovation**
  - How well the research proposes new paradigms or challenges existing paradigms in one or more of the following ways: concept or question, research methods or technologies, adaptations of existing methods or technologies, or looks at existing problems or issues from a new perspective.
  - If applicable, to what degree the potential level of gain for the research and/or patient community justifies the risk of the proposed research project.
  - To what extent the proposed research represents more than an incremental advance.
- **Impact**
  - How well the proposed research project addresses the FY26 BMFRP Focus Area(s).
  - How the research project will make an important contribution to understanding of the causes and/or the progression of BMF diseases, realizing improvements in patient care and/or finding a cure.
  - To what degree the anticipated short-term outcome(s)/product(s) (intellectual and/or tangible) will drive the BMF field forward and support new avenues for research or clinical care.
  - How well the anticipated long-term gains from this research will yield relevant results for BMF disease research or patient care.
  - If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Personnel**
  - How appropriate the levels of effort are for successful conduct of the proposed work.
  - To what degree the expertise and background of the research team are appropriate to accomplish the proposed study.
  - For EIs only:
    - To what degree the BMF disease-related expertise and background of the EI are appropriate to accomplish the proposed work.
  - For ECIs only:
    - Whether the PI's previous training supports the abilities of the ECI to accomplish the proposed work.
    - Whether the institution, through its Letter(s) of Organizational Support, has demonstrated commitment (i.e., independent laboratory space, funding, etc.) to establish a career for the ECI in BMF disease research.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Research Sharing Plan**
  - To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.
- **Translation Potential**
  - How well the application describes the next steps to translate study results following the completion of the proposed study.
  - To what degree the application will leverage collaborations with clinicians or physician-scientists to ensure potential translation of study findings.
- **Budget**
  - Whether the **total** costs exceed the allowable total costs as published in the program announcement.
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research.
  - How well research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
  - Whether the quality and extent of institutional support are appropriate for the proposed research.
  - If applicable, to what degree the intellectual and material property plan is appropriate.
- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 BMFRP, as evidenced by the following:
  - Adherence to the intent of the funding opportunity
  - Program portfolio composition
  - Relative impact
  - Relative innovation
  - Translation potential

6.3. Application Review and Selection Process

6.3.1. Pre-Application

Following the pre-application screening, PIs will be notified as to whether they are invited to submit full applications. The estimated date when PIs can expect to receive notification of an invitation to submit a full application is indicated in Section 1, Basic Information About the Funding Opportunity. No feedback (e.g., a critique of the pre-application's strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review.*** Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign

entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the BMFRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding administrative requirements and national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee (IACUC), IRB or Ethics Committee (EC) review.

8.2. Reporting

Annual technical progress reports as well as a final technical progress report will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

PHS Inclusion Enrollment Reporting (Required for research proposing clinical research): Enrollment reporting on the basis of sex, race and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on eBRAP.

Award Expiration Transition Plan: An Award Expiration Transition Plan, using the template available on eBRAP, must be submitted with the final progress report.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations.

8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of preproposal and full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- Submission of an application for which a letter of invitation was not received.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 BMFRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b)

cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.

- The application fails to conform to this program announcement description.
- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The PI does not meet the eligibility criteria.
- The invited application proposes a different research project than that described in the pre-application.
- The application does not address at least one of the FY26 BMFRP Focus Area(s).
- A clinical trial is proposed.
- If an investigator is named as a PI on more than two BMFRP IDA applications, only the first two applications received will be accepted; additional applications will be administratively withdrawn

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded
SF424 Research & Related Application for Federal Assistance ***(Grants.gov submissions only)***	☐
Summary (Tab 1) and Application Contacts (Tab 2) ***(eBRAP submissions only)***	☐
Attachments	
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐
Statement of Work – Attachment 5, upload as "SOW.pdf"	☐
Innovation Statement – Attachment 6, upload as "Innovation.pdf"	☐
Impact Statement – Attachment 7, upload as "Impact.pdf"	☐
Translation Potential Statement – Attachment 8, upload as "Translation.pdf"	☐
Early-Career Investigator Eligibility Statement (if applicable) – Attachment 9, upload as "ECIeligibility.pdf"	☐
Representations *(Grants.gov submissions only)* – Attachment 10, upload as "RequiredReps.pdf"	☐
Suggested Intragovernmental/Intramural Budget Form *(if applicable)* – Attachment 11, upload as "IGBudget.pdf"	☐
Additional Application Materials	
Research & Related Senior/Key Person Profile (Expanded)	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐
Research & Related Budget	☐
Project/Performance Site Location(s)	☐
Research & Related Subaward Budget Attachment(s) *(if applicable)*	☐

Appendix 2. Acronym List

BMFRP	Bone Marrow Failure Research Program
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ECI	Early Career Investigator
EI	Established Investigator
ET	Eastern Time
FAD	Funding Authorization Document
FDA	U.S. Food and Drug Administration
FY	Fiscal Year
IACUC	Institutional Animal Care and Use Committee
IDA	Idea Development Award
IRB	Institutional Review Board
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
ORRC	Office of Research and Regulatory Compliance
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
UEI	Unique Entity Identifier
URL	Uniform Resource Locator

USC	United States Code
VA	U.S. Department of Veterans Affairs